Ferozsons Laboratories Ltd 2024 AR2

The report highlights Ferozsons Laboratories Limited's performance and initiatives for the fiscal year 2023-2024. The company expanded its healthcare portfolio with key launches like Ferulin, Pakistan's first locally manufactured human insulin, and Sematide, a locally produced GLP-1 agonist, to address the rising prevalence of diabetes. Ferozsons also entered into a voluntary licensing agreement with Gilead Sciences to manufacture and distribute generic lenacapavir for HIV treatment and prevention. On the environmental front, the company invested in renewable energy by operating a one-megawatt solar power plant and initiating the installation of a second one-megawatt plant. Additionally, Ferozsons demonstrated its commitment to social responsibility through community care initiatives, including the Ferozsons Initiative for Research Excellence (FIRE) and the Will-Med forum to empower women in medicine.

Company: Ferozsons Laboratories Ltd

Sector: Health Care

Country: Pakistan

Year: 2024

Type: AR2

Pages: 218

Back to company

Ferozsons Laboratories Ltd

Ferozsons Laboratories Ltd 2024 Annual Report

Annual Report

The report highlights Ferozsons Laboratories Limited's performance and initiatives for the fiscal year 2023-2024. The company expanded its healthcare portfolio with key launches like Ferulin, Pakistan's first locally manufactured human insulin, and Sematide, a locally produced GLP-1 agonist, to address the rising prevalence of diabetes. Ferozsons also entered into a voluntary licensing agreement with Gilead Sciences to manufacture and distribute generic lenacapavir for HIV treatment and prevention. On the environmental front, the company invested in renewable energy by operating a one-megawatt solar power plant and initiating the installation of a second one-megawatt plant. Additionally, Ferozsons demonstrated its commitment to social responsibility through community care initiatives, including the Ferozsons Initiative for Research Excellence (FIRE) and the Will-Med forum to empower women in medicine.

Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.

Document Details

Report Year

2024

Reporting Period

Jul 1, 2023 - Jun 30, 2024

Fiscal Year

2024

Type

Annual Report with Sustainability Disclosures

Language

English

Pages

 

File Size

 

Standards & Assurance

Materiality Assessment

ESG Data?Experimental — AI-extracted data, may contain inaccuracies

Women on Board

Women in Management

Employees